SB 258719

SB 258719 is a selective 5-HT7 receptor antagonist with high affinity (pKi=7.5) for the receptor. SB 258719 can be used for the research of cancer and neurological disease[1][2][3].

Product Specifications

CAS Number

[195199-95-2]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

5-HT Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/SB_258719.html

Purity

99.0

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=CC(C)=C1)(N(C)[C@H](C)CCN2CCC(C)CC2)=O

Molecular Formula

C18H30N2O2S

Molecular Weight

338.51

Precautions

H315, H319, H335

References & Citations

[1]Thomas DR, et al. Functional characterisation of the human cloned 5-HT7 receptor (long form) ; antagonist profile of SB-258719. Br J Pharmacol. 1998;124 (6) :1300-1306.|[2]Guscott MR, et al. The hypothermic effect of 5-CT in mice is mediated through the 5-HT7 receptor. Neuropharmacology. 2003;44 (8) :1031-1037.|[3]Fatima S, et al. 5-Hydroxytryptamine promotes hepatocellular carcinoma proliferation by influencing β-catenin. Mol Oncol. 2016;10 (2) :195-212.